[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Aaron Cook\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":67},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100642749","phase-4-fluorescent-probe-for-assessment-of-renal-elimination-100642749",false,"NCT07643467","Fluorescent Probe for Assessment of Renal Elimination","FLARE","Inclusion Criteria:\n\n* 18-65 years old\n* critically ill or acutely ill hospitalized patients admitted to the intensive care unit\n* Stable\u002Fnormal renal function\n\nExclusion Criteria:\n\n* Prisoners\n* Pregnant women\n* Laboratory evidence of unstable kidney function (KDIGO AKI stage 1-3--This includes subjects with Scr \\> 1.5x baseline)","ALL","18 Years","65 Years",{"count":20,"type":21},200,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","Accurate measures of kidney function is important for precision dosing of many medications. The current methods of determining kidney function largely hinge on the use of equations that use common laboratory values such as serum creatinine \\& static variables like age \\& weight. These are helpful for trending over time, but often are inaccurate during times of medical illness. Other more accurate methods of measuring kidney function include urine collection, although this is not commonly used because of various reasons that make the collection inconvenient or unreliable. The new transdermal glomerular filtration (tGFR) device permits accurate, real-time evaluation of kidney function. This novel method has not been rigorously compared with urine collection \\& other methods of determining kidney function in hospitalized patients. The goal of the study is to compare tGFR with other accepted methods of determining kidney function.",[27,28],"Augmented Renal Clearance","Critical Illness","NOT_YET_RECRUITING","2026-06-12",{"date":32,"type":33},"2026-06-16","ACTUAL",{"date":35,"type":21},"2026-07",{"date":37,"type":21},"2028-06-30",{"name":39,"class":40},"Aaron Cook","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":41},"100525232","phase-4-telavancin-blood-and-cerebrospinal-fluid-concentrations-in-patients-with-external-ventricular-drainage-100525232","NCT06119061","Telavancin Blood and Cerebrospinal Fluid Concentrations in Patients With External Ventricular Drainage","Inclusion Criteria:\n\n* Adult aged 18-85 years\n* Actively draining ventriculostomy\n\nExclusion Criteria:\n\n* history of hypersensitivity to telavancin or similar agents\n* reduced renal function (estimated creatinine clearance \\\u003C 50\u002Fml) at the time of consent\n* severe anemia (hemoglobin \\\u003C 7gm\u002Fdl)\n* vulnerable population (pregnant, prisoner)\n* concomitant antimicrobial therapy","85 Years",{"count":50,"type":21},20,[24],"The proposed study aims to evaluate the CNS penetration of telavancin in a critically ill population using cerebrospinal fluid (CSF) drawn from external ventricular drains (EVDs). Patients with EVDs were chosen as the target population because they frequently require prolonged admission to the intensive care unit and drainage of CSF in order to prevent hydrocephalus. The estimated sample size is 20 subjects. This is a prospective cohort of patients with SAH. Patients will be included if they have an in-dwelling EVD, aged 18-85 years old.\n\nSubjects will receive telavancin 10mg\u002Fkg (maximum 1000mg) every 24 hours for 3 consecutive doses. Serial serum and CSF samples will be obtained. An 8-hour urine collection will be completed on study day 2 in order to define the patient's measured creatinine clearance.",[54],"Subarachnoid Hemorrhage, Aneurysmal",[56,57],"pharmacokinetics","augmented renal clearance","RECRUITING","2025-12-23",{"date":61,"type":33},"2025-12-26",{"date":63,"type":33},"2024-07-02",{"date":65,"type":21},"2026-12",{"name":39,"class":40},""]